Bomai Healthcare's GEM IPO passed the listing committee meeting as a solution provider for interventional treatment of complex vascular diseases

Zhitong Finance App learned that on September 16, Guangdong Bomai Medical Technology Co., Ltd. (abbreviation: Bomai Medical) passed the Shenzhen Stock Exchange GEM Listing Committee meeting. The sponsor of the IPO is CICC, which plans to raise 1.2 billion yuan.

According to the prospectus, Bomai Medical focuses on R&D, production and global sales of high-performance interventional vascular medical devices. It is a leading provider of interventional treatment solutions for complex vascular diseases with technology and products in the global industry, and is also a leading R&D and manufacturing enterprise in the field of domestic vascular interventional balloon catheters.

In terms of product system construction, the company has formed a complete product matrix covering multiple treatment scenarios, with more than 50 product lines. The product application areas cover key fields such as coronary intervention, peripheral intervention, neurological intervention, hemodialysis pathways and interventional accessories, including various types of general balloon catheters, functional balloon catheters, pharmaceutical balloon catheters, interventional guides and catheters, various thrombotic treatment devices, calcification devices, energy therapy devices, etc., which can fully meet the diverse clinical needs of complex vascular disease treatment interventions.

The composition of the company's main business by product for each period of the reporting period is as follows:

As a leading company in the field of interventional vascular medical devices, Bomai Medical occupies a leading position in the market with its technical advantages and large-scale production capacity in products such as balloon catheters. According to Frost & Sullivan's data, in 2025, Bomai Medical became the fourth largest in the Chinese coronary balloon dilatation catheter market with an 11.0% market share and the number one domestic brand; with a 6.5% market share, it became the fifth largest in the Chinese peripheral artery balloon dilatation catheter market.

On the financial side, in 2023, 2024 and 2025, the company achieved operating income of approximately RMB 335 million, RMB 460 million, and RMB 655 million respectively; for the same period, net profit was RMB 25.9914 million, RMB 76.7847 million, and RMB 8.0499 million, respectively.